In mouse models of solid tumors, CAR T cells expressing a chimeric construct comprising the extracellular domain of PD-1 and the cytoplasmic signaling domains of CD28 demonstrated improved antitumor activity associated with decreased susceptibility to tumor-induced hypofunction, and attenuation of inhibitory-receptor expression (150). This evidence concerns the gene PDCD1 and neoplasm.